Kinnevik Results Presentation Deck
Intro
HIGHLIGHTS IN THE QUARTER
Key Events
Led Spring Health's most recent funding round, stepping up our
commitment and increasing our ownership in one of our most
high conviction businesses
●
Net Asset Value
●
Participated in Agreena's funding round, as the company is seeing
strong traction and has scaled its activities by 10x since our first
investment about a year ago
Exited Teladoc, realizing an IRR exceeding 55% since our first
Livongo investment in 2017, releasing an incremental SEK 1.0bn
in the quarter
Ranked first in the Venture Capital category in the Honordex
Inclusive PE & VC Index for the third year in a row. Additionally,
we ranked as the only investor among Equileap's top companies
in Sweden for gender equality, and ranked second globally for
our equal parental leave policy
KINNEVIK
Portfolio Overview
Interim Report Q1 2023
Sustainability
Investment Activities
We invested SEK 814m in the quarter, including:
● SEK 523m into Spring Health
SEK 119m into Agreena
• SEK 104m into Parsley Health
●
In the quarter, we released SEK 1,020m by exiting our remaining
Teladoc investment
Financial Statements
Other
Financial Position
• NAV of SEK 55.5bn (SEK 198 per share), up SEK 2.6bn or 5%
in the quarter
Net cash position of SEK 10.5bn, corresponding to 23% of quarter-
end portfolio value
Kinnevik's ambition is to be Europe's leading listed growth investor. We back the best digital companies for a reimagined everyday and to deliver significant returns.
We understand complex and fast-changing consumer behaviours, and have a strong and expanding portfolio in healthcare, software, marketplaces and climate tech.
As a long-term investor, we strongly believe that investing in sustainable business models and diverse teams will bring the greatest returns for shareholders. We back our
companies at every stage of their journey and invest in Europe and the US. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik's sha-
res are listed on Nasdaq Stockholm's list for large cap companies under the ticker codes KINV A and KINV B.
Events After the Quarter
• Enveda, a biotechnology company tackling drug discovery
through a nature-based approach, was added to our emerging
cluster of life sciences investments with a USD 25m investment
in April
3View entire presentation